ReviewProteomes2018
Clinical Proteomics in Colorectal Cancer, a Promising Tool for Improving Personalised Medicine.
Review in Proteomes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Multi-omics staging of locally advanced rectal cancer predicts treatment response: a pilot study.La Radiologia medica · 2024Article
- Biomarker Identification through Proteomics in Colorectal Cancer.International journal of molecular sciences · 2024Review
- High-throughput proteomics profiling-derived signature associated with chemotherapy response and survival for stage II/III colorectal cancer.NPJ precision oncology · 2023Article
- Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology?Frontiers in oncology · 2023Article
- Bottom-Up Approach to the Discovery of Clinically Relevant Biomarker Genes: The Case of Colorectal Cancer.Cancers · 2022Article
- Label-Free Quantification (LFQ) of Fecal Proteins for Potential Pregnancy Detection in Polar Bears.Life (Basel, Switzerland) · 2022Article
- Long noncoding RNA Ftx regulates the protein expression profile in HCT116 human colon cancer cells.Proteome science · 2022Article
- Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells.BMC cancer · 2022Article
- Review
- Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data.Journal of personalized medicine · 2022Review
- Diagnostic and therapeutic biomarkers in colorectal cancer: a review.American journal of cancer research · 2022Review
- Molecular Network of Colorectal Cancer and Current Therapeutic Options.Frontiers in oncology · 2022Review
- The Roadmap of Colorectal Cancer Screening.Cancers · 2021Review
- The Multiomics Analyses of Fecal Matrix and Its Significance to Coeliac Disease Gut Profiling.International journal of molecular sciences · 2021Review
- Screening of Potential Biomarkers for Gastric Cancer with Diagnostic Value Using Label-free Global Proteome Analysis.Genomics, proteomics & bioinformatics · 2020Article
- Monoamine Oxidase B Expression Correlates with a Poor Prognosis in Colorectal Cancer Patients and Is Significantly Associated with Epithelial-to-Mesenchymal Transition-Related Gene Signatures.International journal of molecular sciences · 2020Article
- Investigating the Proteomic Profile of HT-29 Colon Cancer Cells After Lactobacillus kefiri SGL 13 Exposure Using the SWATH Method.Journal of the American Society for Mass Spectrometry · 2019Article
- Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research.Frontiers in oncology · 2019Review
- In-Depth Characterization of Mass Spectrometry-Based Proteomic Profiles Revealed Novel Signature Proteins Associated with Liver Metastatic Colorectal Cancers.Analytical cellular pathology (Amsterdam) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Colorectal cancer is the third most common and the fourth most lethal cancer worldwide. In most of cases, patients are diagnosed at an advanced or even metastatic stage, thus explaining the high mortality. The lack of proper clinical tests and the complicated procedures currently used for detecting this cancer, as well as for predicting the response to treatment and the outcome of a patient's resistance in guiding clinical practice, are key elements driving the search for biomarkers. In the present overview, the different biomarkers (diagnostic, prognostic, treatment resistance) discovered through proteomics studies in various colorectal cancer study models (blood, stool, biopsies), including the different proteomic techniques used for the discovery of these biomarkers, are reviewed, as well as the various tests used in clinical practice and those currently in clinical phase. These studies define the limits and perspectives related to proteomic biomarker research for personalised medicine in colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.